Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16265961rdf:typepubmed:Citationlld:pubmed
pubmed-article:16265961lifeskim:mentionsumls-concept:C0149722lld:lifeskim
pubmed-article:16265961lifeskim:mentionsumls-concept:C0165032lld:lifeskim
pubmed-article:16265961lifeskim:mentionsumls-concept:C0332237lld:lifeskim
pubmed-article:16265961lifeskim:mentionsumls-concept:C1522326lld:lifeskim
pubmed-article:16265961lifeskim:mentionsumls-concept:C1292734lld:lifeskim
pubmed-article:16265961lifeskim:mentionsumls-concept:C1522168lld:lifeskim
pubmed-article:16265961pubmed:issue9lld:pubmed
pubmed-article:16265961pubmed:dateCreated2005-11-3lld:pubmed
pubmed-article:16265961pubmed:abstractTextLentigo maligna is a special form of in situ cutaneous melanoma that develops on the face of sun worshipers. The topic immunostimulator imiquimod can destroy the neoplasm before it expresses its invasive potential. A strict clinical follow-up of the treated zone must be observed at least 5 years to detect any early sign of recurrence.lld:pubmed
pubmed-article:16265961pubmed:languagefrelld:pubmed
pubmed-article:16265961pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16265961pubmed:citationSubsetIMlld:pubmed
pubmed-article:16265961pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16265961pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16265961pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16265961pubmed:statusMEDLINElld:pubmed
pubmed-article:16265961pubmed:monthSeplld:pubmed
pubmed-article:16265961pubmed:issn0370-629Xlld:pubmed
pubmed-article:16265961pubmed:authorpubmed-author:PiérardG EGElld:pubmed
pubmed-article:16265961pubmed:authorpubmed-author:PaquetPPlld:pubmed
pubmed-article:16265961pubmed:authorpubmed-author:BourguignonRRlld:pubmed
pubmed-article:16265961pubmed:authorpubmed-author:QuatresoozPPlld:pubmed
pubmed-article:16265961pubmed:issnTypePrintlld:pubmed
pubmed-article:16265961pubmed:volume60lld:pubmed
pubmed-article:16265961pubmed:ownerNLMlld:pubmed
pubmed-article:16265961pubmed:authorsCompleteYlld:pubmed
pubmed-article:16265961pubmed:pagination691-4lld:pubmed
pubmed-article:16265961pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16265961pubmed:meshHeadingpubmed-meshheading:16265961...lld:pubmed
pubmed-article:16265961pubmed:meshHeadingpubmed-meshheading:16265961...lld:pubmed
pubmed-article:16265961pubmed:meshHeadingpubmed-meshheading:16265961...lld:pubmed
pubmed-article:16265961pubmed:meshHeadingpubmed-meshheading:16265961...lld:pubmed
pubmed-article:16265961pubmed:meshHeadingpubmed-meshheading:16265961...lld:pubmed
pubmed-article:16265961pubmed:meshHeadingpubmed-meshheading:16265961...lld:pubmed
pubmed-article:16265961pubmed:meshHeadingpubmed-meshheading:16265961...lld:pubmed
pubmed-article:16265961pubmed:meshHeadingpubmed-meshheading:16265961...lld:pubmed
pubmed-article:16265961pubmed:year2005lld:pubmed
pubmed-article:16265961pubmed:articleTitle[How I treat ... lentigo maligna by topical imiquimod].lld:pubmed
pubmed-article:16265961pubmed:affiliationCHR hutois, Service de Dermatologie, Huy.lld:pubmed
pubmed-article:16265961pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16265961pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:16265961pubmed:publicationTypeCase Reportslld:pubmed